Weekly TechBio News (I)
Latest News: Lantern Pharma, Insilico Medicine, Manas AI, LinkGevity, Certara, Tevogen Bio, Retro Biosciences, Model Medicine and Isomorphic Labs
For today’s latest TechBio news:
🛵 Weekly TechBio News (I)
Latest News: Lantern Pharma, Insilico Medicine, Manas AI, LinkGevity, Certara, Tevogen Bio, Retro Biosciences, Model Medicine and Isomorphic Labs
🛵 Weekly TechBio News (II)
“Without deviation from the norm, progress is not possible.”
Frank Zappa
Weekly TechBio News (I)
🪐 Lantern Pharma Inc
Lantern Pharma (NASDAQ: LTRN) announced on January 27, 2025 advancements in the application of its RADR AI platform to accelerate and optimize the development of antibody-drug conjugates (ADCs) (Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer) and is actively advancing multiple ADC candidates through preclinical development, including a promising collaboration with the prestigious MAGICBULLET::Reloaded Initiative at the University of Bielefeld in Germany.
More specifically, in a study published in PLOS ONE (Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis), Lantern Pharma demonstrated how their AI-driven approach successfully identified 82 promising ADC targets and 290 target-indication combinations, while also validating 729 potential payload molecules from a screening of over 50,000 compounds. The key highlights of the AI-powered ADC module include:
Successful identification of 22 clinically proven targets with established therapeutic potential.
Discovery of 60 novel targets that present significant opportunities.
Development of proprietary mutation-specific targeting capabilities that enable improved clinical trial design, enhanced precision in indication selection and more accurate patient response predictions.
Establishment of a framework that could reduce ADC development costs by up to 60% and accelerate development timelines by 30-50%.
Creation of a highly scalable, ML ready approach that leverages the RADR™ AI platform to systematically evaluate thousands of potential tumor sub-types and indications.
Furthermore, the highlights of Lantern’s AI-Powered Pipeline are:
LP-184 continues to advance through its Phase 1a first-in-human trial (NCT05933265) across multiple solid tumor indications.
Patients with recurrent glioblastoma (GBM) have been enrolled in the LP-184 Phase 1a trial at 2 academic centers, including Johns Hopkins and 1 community site. The data will help guide later stage clinical development planned to be sponsored by Starlight Therapeutics (Lantern’s subsidiary) during early 2025.
LP-184, which will be developed as STAR-001 for CNS and other neuro-oncology indications, received Fast Track Designation in GBM from the FDA.
Three U.S. FDA Rare Pediatric Disease Designations were granted to LP-184 in three ultra rare children’s cancers.
LP-284 Phase 1a clinical trial: They are in the process of opening additional hematology-focused sites later this year, with the potential to advance to Phase 1b or 2 by early to mid 2025.
LP-300 in the Harmonic™ Phase 2 Clinical Trial for never-smoker patients with non-small cell lung cancer (NSCLC) demonstrated encouraging preliminary results when combined with standard-of-care chemotherapy (pemetrexed and carboplatin), achieving an 86% clinical benefit rate and a 43% objective response rate.
The Harmonic™ Trial has been expanded to both Japan and Taiwan with an expected 10 sites in East Asia; 5 in each country where the population of never-smokers is 33 to 35 percent of new cases in NSCLC.
For more details:
